Related references
Note: Only part of the references are listed.Frequency of the PNPLA3 rs738409 polymorphism and other genetic loci for liver disease in a Guatemalan adult population
Mariana Lazo et al.
LIVER INTERNATIONAL (2022)
Contribution of a genetic risk score to ethnic differences in fatty liver disease
Maddie J. Kubiliun et al.
LIVER INTERNATIONAL (2022)
Genetic risk scores and personalization of care in fatty liver disease
Cristiana Bianco et al.
CURRENT OPINION IN PHARMACOLOGY (2021)
PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date
Alessandro Cherubini et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2021)
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
V. Ratziu et al.
NATURE MEDICINE (2021)
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis
Jorn M. Schattenberg et al.
LIVER INTERNATIONAL (2021)
Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial
Yvo J. M. Op den Kamp et al.
DIABETES CARE (2021)
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
Rohit Loomba et al.
GASTROENTEROLOGY (2021)
Redefining non-alcoholic fatty liver disease: what's in a name?
[Anonymous]
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort
Quentin M. Anstee et al.
JOURNAL OF HEPATOLOGY (2020)
The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success
Joost P. H. Drenth et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
Gopanandan Parthasarathy et al.
HEPATOLOGY COMMUNICATIONS (2020)
The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
Aino Latva-Rasku et al.
DIABETES CARE (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Insulin Resistance Exacerbates Genetic Predisposition to Nonalcoholic Fatty Liver Disease in Individuals Without Diabetes
Llilda Barata et al.
HEPATOLOGY COMMUNICATIONS (2019)
Four-Week Omega-3 Supplementation in Carriers of the Prosteatotic PNPLA3 p.I148M Genetic Variant: An Open-Label Study
Clara-Sophie Kuttner et al.
LIFESTYLE GENOMICS (2019)
Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids
Panu K. Luukkonen et al.
JCI INSIGHT (2019)
Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver
P. Dongiovanni et al.
JOURNAL OF INTERNAL MEDICINE (2018)
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
Jan W. Eriksson et al.
DIABETOLOGIA (2018)
Human-based systems: Mechanistic NASH modelling just around the corner?
Joost Boeckmans et al.
PHARMACOLOGICAL RESEARCH (2018)
PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease
Jin-Zhi Wang et al.
WORLD JOURNAL OF CLINICAL CASES (2018)
A prospective study to evaluate the efficacy of a standardized low calorie diet (HEPAFAST®) according to PNPLA3 genotype in patients with Non Alcoholic Fatty Liver Disease (NAFLD) – 2 months data (interim analysis)
M Teufelhart et al.
ZEITSCHRIFT FUR GASTROENTEROLOGIE (2017)
Intensive lifestyle treatment for non-alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment
B. G. P. Koot et al.
INTERNATIONAL JOURNAL OF OBESITY (2016)
Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study
Marcin Krawczyk et al.
DIGESTION (2016)
PNPLA3 gene in liver diseases
Eric Trépo et al.
JOURNAL OF HEPATOLOGY (2016)
Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial
Eleonora Scorletti et al.
JOURNAL OF HEPATOLOGY (2015)
PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease
Jiayun Shen et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells
Carlo Pirazzi et al.
HUMAN MOLECULAR GENETICS (2014)
Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
Paola Dongiovanni et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Weight loss allows the dissection of the interaction between abdominal fat and PNPLA3 (adiponutrin) in the liver damage of obese children
Pierluigi Marzuillo et al.
JOURNAL OF HEPATOLOGY (2013)
Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial
Vincent Wai-Sun Wong et al.
JOURNAL OF HEPATOLOGY (2013)
The I148M Variant of PNPLA3 Reduces the Response to Docosahexaenoic Acid in Children with Non-Alcoholic Fatty Liver Disease
Valerio Nobili et al.
JOURNAL OF MEDICINAL FOOD (2013)
The global NAFLD epidemic
Rohit Loomba et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Docosahexaenoic acid for the treatment of fatty liver: Randomised controlled trial in children
V. Nobili et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2013)
PNPLA3 I148M polymorphism and progressive liver disease
Paola Dongiovanni et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans
Ksenia Sevastianova et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2011)
A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis
Shaoqing He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Stefano Romeo et al.
NATURE GENETICS (2008)
Share Paper
